Axa
DYN icon

Axa’s Dyne Therapeutics DYN Stock Holding History

Axa’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-162,745
Closed -$1.55M – 372
2025
Q2 		$1.55M Sell
162,745
-89,072
-35% -$981K ﹤0.01% 812
2025
Q1 		$2.63M Buy
251,817
+63,166
+33% +$904K 0.01% 684
2024
Q4 		$4.44M Sell
188,651
-300
-0.2% -$8.87K 0.01% 570
2024
Q3 		$6.79M Sell
188,951
-21,198
-10% -$844K 0.02% 472
2024
Q2 		$7.42M Sell
210,149
-68,417
-25% -$1.99M 0.02% 450
2024
Q1 		$7.91M Sell
278,566
-271,758
-49% -$6.15M 0.02% 452
2023
Q4 		$7.32M Buy
550,324
+74,298
+16% +$726K 0.02% 465
2023
Q3 		$4.27M Sell
476,026
-1,704
-0.4% -$18.4K 0.02% 565
2023
Q2 		$5.37M Buy
477,730
+53,617
+13% +$633K 0.02% 539
2023
Q1 		$4.89M Buy
424,113
+55,328
+15% +$719K 0.02% 570
2022
Q4 		$4.27M Buy
+368,785
New +$4.27M 0.02% 643

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Axa's DYN Position: Q3 2025 in Review

Axa sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 162,745 shares — an estimated $1.55M sold.

Axa first reported a position in DYN in Q4 2022 and held it in 11 quarters. The position peaked at $7.91M in Q1 2024. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • Axa reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 162,745 Dyne Therapeutics shares in Q3 2025, an estimated $1.55M.
  • Axa first reported a position in Dyne Therapeutics in Q4 2022 and held it in 11 quarters.
  • Axa's Dyne Therapeutics position peaked at $7.91M in Q1 2024.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.